Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-579P is a processed pseudogene copy of the U6 small nuclear RNA (snRNA) gene, identified in the human genome as a result of retrotransposition events, typically involving LINE elements (L1, L2, RTE). Unlike the functional U6 snRNA, which participates in pre-mRNA splicing inside the spliceosome complex, pseudogenes such as RNU6-579P do not encode functional products and are generally regarded as “genomic fossils” representing past duplication and retrotransposition events. U6 snRNA itself is critical for splicing, but the RNU6-579P pseudogene is noncoding and inactive. There are many such snRNA pseudogenes scattered throughout the vertebrate genome, reflecting the historical importance of snRNA genes for eukaryotic gene regulation. RNU6-579P has no established role as a therapeutic target or biomarker and is not implicated directly in disease biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 579, pseudogene (RNU6-579P).